Skip to main content
logo
ZyVersa Therapeutics, Inc. (ZVSA)
OTCMKTS · Delayed Price · Currency is USD
0.1160
0.00 (0.00%)
At close: Jul 28, 2026

ZyVersa Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-24.49-24.95-9.41-98.3-14.12-8.08
Depreciation & Amortization
--0.010.010.010.01
Other Amortization
0.060.06--0.040.32
Asset Writedown & Restructuring Costs
18.6518.65-93.33--
Stock-Based Compensation
0.120.220.711.193.584.14
Other Operating Activities
-0.26-0.610.21-7.56-0.05-0.44
Change in Accounts Payable
0.610.690.892.414.54-0.31
Change in Other Net Operating Assets
1.160.830.080.191.12-0.71
Operating Cash Flow
-4.14-5.11-7.52-8.72-4.89-5.08
Operating Cash Flow Growth
------

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-----5.23
Net Debt Issued (Repaid)
1----5.23
Issuance of Common Stock
2.052.056.5419.08--
Repurchase of Common Stock
----0.01--
Other Financing Activities
-0.221.63-0.63-2.42-0.1-
Financing Cash Flow
2.833.695.915.961.875.23

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-1.31-1.43-1.61-2.76-3.020.15

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Levered Free Cash Flow
-2.18-2.88-4.09-5.46-1.65-2.02
Unlevered Free Cash Flow
-1.85-2.56-3.92-5.46-1.43-1.83

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
1.771.520.972.65.66-1.02